Podcast appearances and mentions of Scott J Antonia

In this activity, experts in the management of patients with non–small cell lung cancer (NSCLC) discuss the new standard of care for stage III locally advanced unresectable NSCLC following the recent approval of checkpoint inhibitor therapy for patients who have not progressed following chemoradiation therapy. In addition, the faculty consider how immunotherapy should be integrated into the management of patients with stage III NSCLC, the practical nuances of use, including timing and duration of therapy, as well as management of overlapping and nonoverlapping adverse effects, and immunotherapy-based rational treatment approaches that are being evaluated in neoadjuvant and adjuvant settings in earlier stages of lung cancer. Upon completion of this activity, participants will be able to: Describe the rationale for use of immunotherapy in earlier stages (I-III) of NSCLC, Evaluate the latest data on efficacy and safety of immunotherapy in stage III NSCLC, and clinical implications of these data, Discuss the key clinical trials assessing immune-based treatment approaches in locally advanced or earlier stages of lung cancer, Incorporate immunotherapy into treatment plans for patients with stage III or earlier stages of lung cancer, including in the context of clinical practice or clinical trials, based on the latest evidence, best practice recommendations, and patient needs.

In this activity, experts in the management of patients with non–small cell lung cancer (NSCLC) discuss the new standard of care for stage III locally advanced unresectable NSCLC following the recent approval of checkpoint inhibitor therapy for patients who have not progressed following chemoradiation therapy. In addition, the faculty consider how immunotherapy should be integrated into the management of patients with stage III NSCLC, the practical nuances of use, including timing and duration of therapy, as well as management of overlapping and nonoverlapping adverse effects, and immunotherapy-based rational treatment approaches that are being evaluated in neoadjuvant and adjuvant settings in earlier stages of lung cancer. Upon completion of this activity, participants will be able to: Describe the rationale for use of immunotherapy in earlier stages (I-III) of NSCLC, Evaluate the latest data on efficacy and safety of immunotherapy in stage III NSCLC, and clinical implications of these data, Discuss the key clinical trials assessing immune-based treatment approaches in locally advanced or earlier stages of lung cancer, Incorporate immunotherapy into treatment plans for patients with stage III or earlier stages of lung cancer, including in the context of clinical practice or clinical trials, based on the latest evidence, best practice recommendations, and patient needs.

In this activity, experts in the management of patients with non–small cell lung cancer (NSCLC) discuss the new standard of care for stage III locally advanced unresectable NSCLC following the recent approval of checkpoint inhibitor therapy for patients who have not progressed following chemoradiation therapy. In addition, the faculty consider how immunotherapy should be integrated into the management of patients with stage III NSCLC, the practical nuances of use, including timing and duration of therapy, as well as management of overlapping and nonoverlapping adverse effects, and immunotherapy-based rational treatment approaches that are being evaluated in neoadjuvant and adjuvant settings in earlier stages of lung cancer. Upon completion of this activity, participants will be able to: Describe the rationale for use of immunotherapy in earlier stages (I-III) of NSCLC, Evaluate the latest data on efficacy and safety of immunotherapy in stage III NSCLC, and clinical implications of these data, Discuss the key clinical trials assessing immune-based treatment approaches in locally advanced or earlier stages of lung cancer, Incorporate immunotherapy into treatment plans for patients with stage III or earlier stages of lung cancer, including in the context of clinical practice or clinical trials, based on the latest evidence, best practice recommendations, and patient needs.

In this activity, experts in the management of patients with non–small cell lung cancer (NSCLC) discuss the new standard of care for stage III locally advanced unresectable NSCLC following the recent approval of checkpoint inhibitor therapy for patients who have not progressed following chemoradiation therapy. In addition, the faculty consider how immunotherapy should be integrated into the management of patients with stage III NSCLC, the practical nuances of use, including timing and duration of therapy, as well as management of overlapping and nonoverlapping adverse effects, and immunotherapy-based rational treatment approaches that are being evaluated in neoadjuvant and adjuvant settings in earlier stages of lung cancer. Upon completion of this activity, participants will be able to: Describe the rationale for use of immunotherapy in earlier stages (I-III) of NSCLC, Evaluate the latest data on efficacy and safety of immunotherapy in stage III NSCLC, and clinical implications of these data, Discuss the key clinical trials assessing immune-based treatment approaches in locally advanced or earlier stages of lung cancer, Incorporate immunotherapy into treatment plans for patients with stage III or earlier stages of lung cancer, including in the context of clinical practice or clinical trials, based on the latest evidence, best practice recommendations, and patient needs.

In this activity, experts in the management of patients with non–small cell lung cancer (NSCLC) discuss the new standard of care for stage III locally advanced unresectable NSCLC following the recent approval of checkpoint inhibitor therapy for patients who have not progressed following chemoradiation therapy. In addition, the faculty consider how immunotherapy should be integrated into the management of patients with stage III NSCLC, the practical nuances of use, including timing and duration of therapy, as well as management of overlapping and nonoverlapping adverse effects, and immunotherapy-based rational treatment approaches that are being evaluated in neoadjuvant and adjuvant settings in earlier stages of lung cancer. Upon completion of this activity, participants will be able to: Describe the rationale for use of immunotherapy in earlier stages (I-III) of NSCLC, Evaluate the latest data on efficacy and safety of immunotherapy in stage III NSCLC, and clinical implications of these data, Discuss the key clinical trials assessing immune-based treatment approaches in locally advanced or earlier stages of lung cancer, Incorporate immunotherapy into treatment plans for patients with stage III or earlier stages of lung cancer, including in the context of clinical practice or clinical trials, based on the latest evidence, best practice recommendations, and patient needs.

In this activity, experts in the management of patients with non–small cell lung cancer (NSCLC) discuss the new standard of care for stage III locally advanced unresectable NSCLC following the recent approval of checkpoint inhibitor therapy for patients who have not progressed following chemoradiation therapy. In addition, the faculty consider how immunotherapy should be integrated into the management of patients with stage III NSCLC, the practical nuances of use, including timing and duration of therapy, as well as management of overlapping and nonoverlapping adverse effects, and immunotherapy-based rational treatment approaches that are being evaluated in neoadjuvant and adjuvant settings in earlier stages of lung cancer. Upon completion of this activity, participants will be able to: Describe the rationale for use of immunotherapy in earlier stages (I-III) of NSCLC, Evaluate the latest data on efficacy and safety of immunotherapy in stage III NSCLC, and clinical implications of these data, Discuss the key clinical trials assessing immune-based treatment approaches in locally advanced or earlier stages of lung cancer, Incorporate immunotherapy into treatment plans for patients with stage III or earlier stages of lung cancer, including in the context of clinical practice or clinical trials, based on the latest evidence, best practice recommendations, and patient needs.

In this activity, experts in the management of patients with non–small cell lung cancer (NSCLC) discuss the new standard of care for stage III locally advanced unresectable NSCLC following the recent approval of checkpoint inhibitor therapy for patients who have not progressed following chemoradiation therapy. In addition, the faculty consider how immunotherapy should be integrated into the management of patients with stage III NSCLC, the practical nuances of use, including timing and duration of therapy, as well as management of overlapping and nonoverlapping adverse effects, and immunotherapy-based rational treatment approaches that are being evaluated in neoadjuvant and adjuvant settings in earlier stages of lung cancer. Upon completion of this activity, participants will be able to: Describe the rationale for use of immunotherapy in earlier stages (I-III) of NSCLC, Evaluate the latest data on efficacy and safety of immunotherapy in stage III NSCLC, and clinical implications of these data, Discuss the key clinical trials assessing immune-based treatment approaches in locally advanced or earlier stages of lung cancer, Incorporate immunotherapy into treatment plans for patients with stage III or earlier stages of lung cancer, including in the context of clinical practice or clinical trials, based on the latest evidence, best practice recommendations, and patient needs.

In this activity, experts in the management of patients with non–small cell lung cancer (NSCLC) discuss the new standard of care for stage III locally advanced unresectable NSCLC following the recent approval of checkpoint inhibitor therapy for patients who have not progressed following chemoradiation therapy. In addition, the faculty consider how immunotherapy should be integrated into the management of patients with stage III NSCLC, the practical nuances of use, including timing and duration of therapy, as well as management of overlapping and nonoverlapping adverse effects, and immunotherapy-based rational treatment approaches that are being evaluated in neoadjuvant and adjuvant settings in earlier stages of lung cancer. Upon completion of this activity, participants will be able to: Describe the rationale for use of immunotherapy in earlier stages (I-III) of NSCLC, Evaluate the latest data on efficacy and safety of immunotherapy in stage III NSCLC, and clinical implications of these data, Discuss the key clinical trials assessing immune-based treatment approaches in locally advanced or earlier stages of lung cancer, Incorporate immunotherapy into treatment plans for patients with stage III or earlier stages of lung cancer, including in the context of clinical practice or clinical trials, based on the latest evidence, best practice recommendations, and patient needs.